Skip to main content
Quest Diagnostics

Epidemiologic Burden of Hepatitis D Virus in the United States

CROI 2024

Conference on Retroviruses and Opportunistic Infections

Denver, CO, March 3-6, 2024

Poster presentation: Epidemiologic Burden of Hepatitis D Virus in the United States

Authors: Marlowe EM, Swanson B, Realegeno SE, Kagan RM, Meyer III WA

Specialty: Infectious disease

Related content

Conference Presentation
Seroprevalence of Hepatitis D Virus (HDV) antibodies in patient specimens with detectable HDV RNA
Conference Presentation
Very low rates of hepatitis delta virus testing among a large national cohort of patients with chronic hepatitis B infection
Publication
HDV RNA assays: performance characteristics, clinical utility and challenges
Publication
Hepatitis C Virus Testing During Pregnancy Following Universal Screening Recommendations
Publication
Hepatitis C virus clearance cascade — United States, 2013–2022
Publication
Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination
Test FAQ
HBV screen panel with reflexes
On-Demand Webinar
HBV Webinar: From Screening to Functional Cure

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.